Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Philippines: Results from the Dyslipidemia international study II
https://doi.org/10.47895/amp.v52i6.295
- Author:
Rody G. Sy
1
;
Maria Teresa B. Abola
2
;
Baishali Ambegaonkar
3
;
Roy Joseph M. Barcinas
4
;
Philippe Brudi
3
;
Martin Horack
5
;
Dominik Lautsch
3
;
Aurora G. Macaballug
6
;
Eugenio B. Reyes
7
;
Noel L. Rosas
8
;
Domingo P. Solimen
9
;
Ami Vyas
10
;
Christy S. Yao
11
;
Maria Delfa T. Zanoria
12
;
Anselm K. Gitt
5
,
13
Author Information
1. College of Medicine, University of the Philippines Manila
2. Philippine Heart Center, Quezon City, Philippines
3. Merck and Co., Inc., Kenilworth, NJ, USA
4. Alexian Brothers, Davao City, Philippines
5. Stiftung Institut fur Herzinfarktforschung, Ludwigshafen, Germany
6. Las Pinas Doctors Hospial, Las Pinas City, Philippines
7. Manila Doctors Hospital, Manila, Philippines
8. Makati Medical Center, Makati City, Philippines
9. Baguio General Hospital, Baguio City, Philippines
10. University of Rhode Island, College of Pharmacy, Department of Pharmacy Practice, Kingston, RI, USA
11. The Medical City, Pasig City, Philippines
12. Perpetual Succour Hospital, Cebu City, Philippines
13. Klinikum der Stadt Ludwigshafen, Medizinische Klinik B, Ludwigshafen, Germany
- Publication Type:Journal Article
- MeSH:
Cholesterol;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Coronary Disease;
Acute Coronary Syndrome;
Myocardial Infarction
- From:
Acta Medica Philippina
2018;52(61):494-501
- CountryPhilippines
- Language:English
-
Abstract:
Objective:To quantify the extent of hyperlipidemia and its treatment in patients with stable coronary heart disease (CHD) or an acute coronary syndrome (ACS) in the Philippines.
Methods:The Dyslipidemia International Study (DYSIS) II was an observational, multinational study conducted in patients aged ≥18 years with stable CHD or being hospitalized with an ACS. A full lipid profile was evaluated at baseline, and for the ACS cohort, at 4 months after discharge from hospital. Achievement of low-density lipoprotein cholesterol (LDL-C) targets and the use of lipid-lowering therapy (LLT) were assessed.
Results:A total of 232 patients were enrolled from 10 centers in the Philippines, 184 with stable CHD and 48 being hospitalized with an ACS. The mean LDL-C level for the CHD patients was 88.0±40.1 mg/dL, with 33.3% achieving the target of <70 mg/dL recommended for very high-risk patients. For the ACS cohort, the mean LDL-C level was 109.0±48.5 mg/dL, with target attainment of 25.0%. The majority of the CHD cohort was being treated with LLT (97.3%), while 55.3% of the ACS patients were receiving LLT prior to hospitalization, rising to 100.0% at follow-up. There was little use of non-statins.
Conclusions:For these very high-risk patients from the Philippines, LDL-C target attainment was poor. Opportunities for better monitoring and treatment of these subjects are being missed.
- Full text:295-Article Text-84220-1-10-20221020.pdf
